ren-1654
Small moleculeexperimental
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Nov 2, 1999 (NCT00002209)
Timeline
Indications
Mechanism of action
- TNF-alphaINHIBITOR
TNF inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- cpi 1189
- cpi-1189
- cpi-1189
- cpi-1189
- ren-1654
- ren-1654
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00107055 | Phase 2 | Dec 1, 2003 | Renovis |
| NCT00099528 | Phase 2 | Aug 1, 2003 | Renovis |
| NCT00002209 | Phase 1 | Nov 2, 1999 | Centaur Pharmaceuticals |
| NCT00002414 | Phase 2 | Nov 2, 1999 | Centaur Pharmaceuticals |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Centaur Pharmaceuticals | For profit | 2 | 2 | 2 | 1999 |
| Renovis | For profit | 2 | 2 | 1 | 2003 |
2 organizations
Page 1 / 1